APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Open Access
- 7 January 2021
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 107 (2), 403-416
- https://doi.org/10.3324/haematol.2020.259531
Abstract
APR-246 is a promising new therapeutic agent that targets p53 mutated proteins in myelodysplastic syndromes and in acute myeloid leukemia. APR-246 reactivates the transcriptional activity of p53 mutants by facilitating their binding to DNA target sites. Recent studies in solid cancers have found that APR-246 can also induce p53-independent cell death. In this study, we demonstrate that AML cell death occurring early after APR-246 exposure is suppressed by iron chelators, lipophilic antioxidants and inhibitors of lipid peroxidation, and correlates with the accumulation of markers of lipid peroxidation, thus fulfilling the definition of ferroptosis, a recently described cell death process. The capacity of AML cells to detoxify lipid peroxides by increasing their cystine uptake to maintain major antioxidant molecule glutathione biosynthesis after exposure to APR-246 may be a key determinant of sensitivity to this compound. The association of APR-246 with induction of ferroptosis (either by pharmacological compounds, or genetic inactivation of SLC7A11 or GPX4) had a synergistic effect on the promotion of cell death, both in vivo and ex vivo.Keywords
This publication has 49 references indexed in Scilit:
- Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease modelsCell Death & Disease, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 KinaseCell, 2012
- p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinomaOral Oncology, 2011
- APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cellsEuropean Journal of Haematology, 2010
- Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosisOncogene, 2009
- MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cellsInternational Journal of Cancer, 2009
- PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletionBritish Journal of Haematology, 2005
- PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosisOncogene, 2005
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002